In a paradigm-breaking study, researchers have discovered a novel way the immune system, specifically Tcells, attack their target cells, reshaping long-held assumptions in immunology and demonstrating direct implications for the field of cancer immunology and bone marrow transplantation. The team consists of Dr. Pavan Reddy, director of the Dan L Duncan Comprehensive Cancer Center at Baylor College of Medicine (BCM) and his team, in collaboration with Drs. Arul Chinnaiyan, S P Hicks Endowed Professor of Pathology, and Marcin Cieslik, assistant professor of pathology, both from University of Michigan Rogel Cancer Center. The study is published in Nature Immunology.
Rewriting the rules of T cell biology
The immune system relies on molecules called major histocompatibility complexes (MHC) to detect external “threats” to the body, including from cancerous or foreign (allogeneic) cells. Historically, MHC class I molecules were believed to present signals only to CD8+ T cells (“killer” T cells), while MHC II activated CD4+ T cells (“helper” T cells). This division of MHC class roles guided decades of immunology and cancer research.
In an example of collaborative work, Reddy’s graduate students Emma Lauder and Meng-Chih Wu from BCM and Chinnaiyan and Cieslik’s student Mahnoor Gondal, from University of Michigan, worked with colleagues on various components of the work that spanned several years. The work challenges this foundational MHC class-restricted dichotomy and reveals a previously unrecognized role for the class I pathway in CD4+ T cell–mediated immune defense.
How cancer cells become vulnerable
Utilizing advanced transcriptomic and functional studies in experimental mice models and humans, Reddy and colleagues demonstrate that when cancer cells lose MHC I expression—a common strategy to evade CD8+ T cell attack—they become more vulnerable to attack from CD4+ T cells. The authors found that, without MHC I expression, cancer cells are more sensitive to ferroptosis triggered by CD4+ T cells. Ferroptosis is a type of cell death driven by iron and oxidative stress.
The induction of ferroptosis occurred not only in cancer, but also in models of graft-versus-host disease, a significant complication of bone marrow transplant. Chinnaiyan’s team demonstrated that these observations correlated with clinical outcomes by analyzing large transcriptomic and clinical datasets from patients who received checkpoint blocker therapy for solid tumor cancers.
Implications for future immunotherapies
This work shows that reducing expression of MHC I enhances CD4+ T cell-driven killing of target cells, whether allogeneic or cancerous. New strategies to harness these so-called “helpers” could make immunotherapies more potent, especially against tumors that evade CD8+ T cell responses, while also suggesting a role for MHC class I in regulating tissue sensitivity to CD4+ T cell-mediated attack.
“Our work, if further validated, will have implications for T cell-mediated immune responses beyond cancer and transplant immunology,” Reddy said. “This may allow for the development of novel strategies that target MHC class I and CD4+ T cells to leverage the beneficial side of immunity or mitigate unwanted immune responses. https://medicalxpress.com/news/2026-03-previously-unrecognized-immune-response-defense.html
Recent Comments